864070-44-0 | (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$6.00	$4.00
50mg	98%	in stock	$7.00	$5.00
250mg	98%	in stock	$16.00	$11.00
1g	98%	in stock	$53.00	$37.00
5g	98%	in stock	$93.00	$65.00
10g	98%	in stock	$150.00	$105.00
25g	98%	in stock	$307.00	$215.00
100g	98%	in stock	$823.00	$576.00

Description

• Catalog Number: AB52385
• Chemical Name: (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS Number: 864070-44-0
• Molecular Formula: C23H27ClO7
• Molecular Weight: 450.9093
• MDL Number: MFCD22566222
• SMILES: OC[C@H]1O[C@@H](c2ccc(c(c2)Cc2ccc(cc2)O[C@@H]2COCC2)Cl)[C@@H]([C@H]([C@@H]1O)O)O

Computed Properties

• Complexity: 558
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 6
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 6
• XLogP3: 2

Literature

• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  The New England journal of medicine 20151126

• Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

  Clinical pharmacokinetics 20150701

• Empagliflozin for the treatment of type 2 diabetes.

  Expert opinion on pharmacotherapy 20141101

• Empagliflozin (Jardiance) for diabetes.

  The Medical letter on drugs and therapeutics 20141013

• Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.

  Diabetes, obesity & metabolism 20141001

• Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.

  Diabetes care 20140601

• Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.

  Expert opinion on investigational drugs 20140601

• Empagliflozin for the treatment of Type 2 diabetes.

  Expert review of clinical pharmacology 20140501

• Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

  Drugs in context 20140101

• Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin.

  International journal of toxicology 20140101

• Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.

  Advances in therapy 20121001

• Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.

  Diabetes, obesity & metabolism 20120701

• A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.

  Annals of medicine 20120601

• [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].

  Orvosi hetilap 20120506

• Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

  Diabetes, obesity & metabolism 20120101

• Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

  Diabetes, obesity & metabolism 20120101

• Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

  The Journal of clinical endocrinology and metabolism 20100101

• From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.

  Current medical research and opinion 20090301

• Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080901